Literature DB >> 24270207

Hyperphosphorylated tau is elevated in Alzheimer's disease with psychosis.

Patrick S Murray1, Caitlin M Kirkwood2, Megan C Gray2, Kenneth N Fish2, Milos D Ikonomovic3, Ronald L Hamilton4, Julia K Kofler4, William E Klunk5, Oscar L Lopez5, Robert A Sweet6.   

Abstract

Psychosis occurs in 40-60% of Alzheimer's disease (AD) subjects, is heritable, and indicates a more rapidly progressive disease phenotype. Neuroimaging and postmortem evidence support an exaggerated prefrontal cortical synaptic deficit in AD with psychosis. Microtubule-associated protein tau is a key mediator of amyloid-β-induced synaptotoxicity in AD, and differential mechanisms of progressive intraneuronal phospho-tau accumulation and interneuronal spread of tau aggregates have recently been described. We hypothesized that psychosis in AD would be associated with greater intraneuronal concentration of phospho-tau and greater spread of tau aggregates in prefrontal cortex. We therefore evaluated prefrontal cortex phospho-tau in a cohort of 45 AD cases with and without psychosis. Intraneuronal phospho-tau concentration was higher in subjects with psychosis, while a measure of phospho-tau spread, volume fraction, was not. Across groups both measures were associated with lower scores on the Mini-Mental State Examination and Digit Span Backwards test. These novel findings indicate that tau phosphorylation may be accelerated in AD with psychosis, indicating a more dynamic, exaggerated pathology in AD with psychosis.

Entities:  

Keywords:  Alzheimer's disease; Braak stage; Mini-Mental State Examination; psychosis; tau

Mesh:

Substances:

Year:  2014        PMID: 24270207      PMCID: PMC4034758          DOI: 10.3233/JAD-131166

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  68 in total

1.  Incidence of and risk factors for hallucinations and delusions in patients with probable AD.

Authors:  J S Paulsen; D P Salmon; L J Thal; R Romero; C Weisstein-Jenkins; D Galasko; C R Hofstetter; R Thomas; I Grant; D V Jeste
Journal:  Neurology       Date:  2000-05-23       Impact factor: 9.910

2.  Relationships between behavioral syndromes and cognitive domains in Alzheimer disease: the impact of mood and psychosis.

Authors:  Jeremy Koppel; Terry E Goldberg; Marc L Gordon; Edward Huey; Peter Davies; Linda Keehlisen; Sara Huet; Erica Christen; Blaine S Greenwald
Journal:  Am J Geriatr Psychiatry       Date:  2012-11       Impact factor: 4.105

3.  Neurobehaviors and psychotic symptoms in Alzheimer's disease.

Authors:  J S Paulsen; R E Ready; J C Stout; D P Salmon; L J Thal; I Grant; D V Jeste
Journal:  J Int Neuropsychol Soc       Date:  2000-11       Impact factor: 2.892

4.  Delusions in Alzheimer's disease: spet evidence of right hemispheric dysfunction.

Authors:  R T Staff; M F Shanks; L Macintosh; S J Pestell; H G Gemmell; A Venneri
Journal:  Cortex       Date:  1999-09       Impact factor: 4.027

5.  Cerebral correlates of psychotic symptoms in Alzheimer's disease.

Authors:  M S Mega; L Lee; I D Dinov; F Mishkin; A W Toga; J L Cummings
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-08       Impact factor: 10.154

6.  Psychosis in Alzheimer's disease is associated with frontal metabolic impairment and accelerated decline in working memory: findings from the Alzheimer's Disease Neuroimaging Initiative.

Authors:  Jeremy Koppel; Suzanne Sunday; Terry E Goldberg; Peter Davies; Erica Christen; Blaine S Greenwald
Journal:  Am J Geriatr Psychiatry       Date:  2013-03-15       Impact factor: 4.105

Review 7.  Psychosis in Alzheimer's disease.

Authors:  Patrick S Murray; Sanjeev Kumar; Mary Ann A Demichele-Sweet; Robert A Sweet
Journal:  Biol Psychiatry       Date:  2013-10-06       Impact factor: 13.382

Review 8.  Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future.

Authors:  Yonas E Geda; Lon S Schneider; Laura N Gitlin; David S Miller; Gwenn S Smith; Joanne Bell; Jovier Evans; Michael Lee; Anton Porsteinsson; Krista L Lanctôt; Paul B Rosenberg; David L Sultzer; Paul T Francis; Henry Brodaty; Prasad P Padala; Chiadikaobi U Onyike; Luis Agüera Ortiz; Sonia Ancoli-Israel; Donald L Bliwise; Jennifer L Martin; Michael V Vitiello; Kristine Yaffe; Phyllis C Zee; Nathan Herrmann; Robert A Sweet; Clive Ballard; Ni A Khin; Cara Alfaro; Patrick S Murray; Susan Schultz; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2013-04-03       Impact factor: 21.566

9.  The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease.

Authors:  Megan Larson; Mathew A Sherman; Fatou Amar; Mario Nuvolone; Julie A Schneider; David A Bennett; Adriano Aguzzi; Sylvain E Lesné
Journal:  J Neurosci       Date:  2012-11-21       Impact factor: 6.167

10.  Genome-wide association study of Alzheimer's disease with psychotic symptoms.

Authors:  P Hollingworth; R Sweet; R Sims; D Harold; G Russo; R Abraham; A Stretton; N Jones; A Gerrish; J Chapman; D Ivanov; V Moskvina; S Lovestone; P Priotsi; M Lupton; C Brayne; M Gill; B Lawlor; A Lynch; D Craig; B McGuinness; J Johnston; C Holmes; G Livingston; N J Bass; H Gurling; A McQuillin; P Holmans; L Jones; B Devlin; L Klei; M M Barmada; F Y Demirci; S T DeKosky; O L Lopez; P Passmore; M J Owen; M C O'Donovan; R Mayeux; M I Kamboh; J Williams
Journal:  Mol Psychiatry       Date:  2011-10-18       Impact factor: 15.992

View more
  22 in total

1.  Lewy Bodies, Vascular Risk Factors, and Subcortical Arteriosclerotic Leukoencephalopathy, but not Alzheimer Pathology, are Associated with Development of Psychosis in Alzheimer's Disease.

Authors:  Corinne E Fischer; Winnie Qian; Tom A Schweizer; Colleen P Millikin; Zahinoor Ismail; Eric E Smith; Lisa M Lix; Paul Shelton; David G Munoz
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

2.  Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimer's Disease.

Authors:  Josh M Krivinko; Susan L Erickson; Ying Ding; Zhe Sun; Peter Penzes; Matthew L MacDonald; Nathan A Yates; Milos D Ikonomovic; Oscar L Lopez; Robert A Sweet; Julia Kofler
Journal:  Am J Psychiatry       Date:  2018-07-19       Impact factor: 18.112

3.  Increased tau phosphorylation follows impeded dopamine clearance in a P301L and novel P301L/COMT-deleted (DM) tau mouse model.

Authors:  Jeremy Koppel; Heidy Jimenez; Leslie Adrien; Eric H Chang; Anil K Malhotra; Peter Davies
Journal:  J Neurochem       Date:  2018-11-12       Impact factor: 5.372

4.  Total Tau and Phosphorylated Tau Protein Serum Levels in Patients with Schizophrenia Compared with Controls.

Authors:  Ömer Faruk Demirel; Ihsan Cetin; Şenol Turan; Nazım Yıldız; Tarık Sağlam; Alaattin Duran
Journal:  Psychiatr Q       Date:  2017-12

Review 5.  Neuropsychiatric Symptoms in Mild Cognitive Impairment.

Authors:  Damien Gallagher; Corinne E Fischer; Andrea Iaboni
Journal:  Can J Psychiatry       Date:  2017-03       Impact factor: 4.356

Review 6.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

Review 7.  Molecular and cellular mechanism of okadaic acid (OKA)-induced neurotoxicity: a novel tool for Alzheimer's disease therapeutic application.

Authors:  Pradip K Kamat; Shivika Rai; Supriya Swarnkar; Rakesh Shukla; Chandishwar Nath
Journal:  Mol Neurobiol       Date:  2014-04-08       Impact factor: 5.590

Review 8.  Animal Models of Psychosis in Alzheimer Disease.

Authors:  Josh M Krivinko; Jeremy Koppel; Alena Savonenko; Robert A Sweet
Journal:  Am J Geriatr Psychiatry       Date:  2019-05-17       Impact factor: 4.105

9.  The neural signatures of psychoses in Alzheimer's disease: a neuroimaging genetics approach.

Authors:  Riccardo Manca; Antonio F Pardiñas; Annalena Venneri
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-06-21       Impact factor: 5.270

10.  Kalirin reduction rescues psychosis-associated behavioral deficits in APPswe/PSEN1dE9 transgenic mice.

Authors:  Josh M Krivinko; Susan L Erickson; Eric E Abrahamson; Zachary P Wills; Milos D Ikonomovic; Peter Penzes; Robert A Sweet
Journal:  Neurobiol Aging       Date:  2017-02-16       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.